PAVmed Amends Lucid Diagnostics Stake

TL;DR

**PAVmed Inc. just updated its ownership in Lucid Diagnostics, showing its continued stake.**

AI Summary

PAVmed Inc. filed an SC 13D/A Amendment No. 3 on February 20, 2024, regarding its ownership in Lucid Diagnostics Inc. The filing indicates PAVmed Inc. holds Common Stock, par value $0.001 per share, of Lucid Diagnostics Inc. The contact person for this filing is Lishan Aklog, M.D., Chairman and CEO of PAVmed Inc., located at 360 Madison Avenue, 25th Floor, New York, New York 10017.

Why It Matters

This filing updates the public on PAVmed Inc.'s beneficial ownership in Lucid Diagnostics Inc., providing transparency on a significant shareholder's position.

Risk Assessment

Risk Level: low — This is an amendment to a beneficial ownership report, which is a routine disclosure and does not inherently signal high risk.

Key Players & Entities

• PAVmed Inc. (company) — Filing entity and beneficial owner
• Lucid Diagnostics Inc. (company) — Subject company of the filing
• Lishan Aklog, M.D. (person) — Chairman and Chief Executive Officer of PAVmed Inc.
• $0.001 (dollar_amount) — Par value per share of Lucid Diagnostics Common Stock
• February 20, 2024 (date) — Date of filing

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
• $0.52 — ck with a market value of approximately $0.52 per share of the Reporting Person&rsquo

Filing Documents

• formsc13da.htm (SC 13D/A) — 56KB
• 0001493152-24-007235.txt ( ) — 58KB

of this Schedule 13D, which information is incorporated herein by reference

Item 4 of this Schedule 13D, which information is incorporated herein by reference. Item 4. Purpose of the Transaction On February 15, 2024, the Reporting Person distributed to holders of its common and preferred stock, by way of a special in-kind dividend, approximately 3,331,747 of shares of Common Stock (the “ Distribution ”). Based on the number of shares of the Reporting Person’s stock outstanding as of the record date for the Distribution, January 15, 2024, stockholders of the Reporting Person received 0.37709668 of a share of Common Stock for each share of the Reporting Person’s common stock held (in the case of the Reporting Person’s preferred stock, as if such preferred stock had been converted into common stock) as of 5:00 p.m. Eastern Time on the record date. The holder of the Reporting Person’s senior convertible notes waived its right to participate in the Distribution. The Reporting Person will not distribute fractional shares of Common Stock, but rather will round each of its stockholders’ entitlement to shares of Common Stock to the nearest whole number of shares. Based on closing market price of Common Stock on the distribution date, the special dividend reflects a distribution of Common Stock with a market value of approximately $0.52 per share of the Reporting Person’s stock. The Reporting Person is the parent company of the Issuer and, with its ownership of approximately 65.2% of the outstanding shares of Common Stock, has the power to elect all of the directors of the Issuer and to control all matters that would require the vote of a majority of the outstanding shares of Common Stock of the Issuer. The Reporting Person or any of the Principals, respectively, may acquire additional securities of the Issuer and may retain or sell all or a portion of the securities then held in the open market or in privately negotiated transactions. Each of the Reporting Person and each of the Principals, resp

Signatures

Signatures After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. PAVMED INC. Dated: February 20, 2024 By: /s/ Lishan Aklog Lishan Aklog, M.D. Chief Executive Officer

View Full Filing

View this SC 13D/A filing on SEC EDGAR